The Bulletin
Men's Weekly


.

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

  • Written by PR Newswire
Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. Having successfully advanced through single asending dose,SKY-0515 is advancing into the Multiple Ascending Dose portion of its phase 1 study. Huntington's disease is a fatal neurological disease with no curative therapies.

WALTH...

The Bulletin Magazine

How Lawyers in Melbourne Can Resolve Disputes Without Going to Court

Multi Unit Development Builders Melbourne: Maximising Land and Investment Potential

A Complete Checklist for Hiring Reliable Home Removalists in Perth

What is the Difference between Roadside Assistance and Towing?

Don't Renew Your Roadside Assistance Cover Until You Read This!

eCommerce Site Design: Building Modern, High-Performing Online Stores for Australian Businesses

Your Reliable Partner for Every Roadside Emergency

Choosing Waterproofing Membranes for Outdoor Spaces: The Essential Attributes You Need

How Modular Content Accelerates Turnaround for Time-Sensitive Campaigns

How Litigation Lawyers in Sydney Can Help Resolve Disputes Efficiently

Revitalising Homes and Offices with Professional Carpet Cleaning Melbourne

Gum Grafting for Receding Gums: Cost, Recovery Time, and What to Expect